HCA Healthcare Inc. (HCA) reported $78.70B of revenue for the twelve months ended Sep 30, 2026. That is up 5.8% from the year before. Revenue for fiscal 2025 was $75.60B.

Yes. HCA Healthcare Inc. earned $6.78B in net income for the twelve months ended Sep 30, 2026, a net margin of 8.6%.

How much cash and debt does HCA have?

HCA Healthcare Inc. reported $908.00M in cash and cash equivalents and $50.49B of debt on its most recent balance sheet in SEC filings.

How fast is HCA revenue growing?

HCA Healthcare Inc.'s revenue changed +7.1% in fiscal 2025, to $75.60B. Its compound annual growth rate was +8.0% over 5 years.

What is HCA free cash flow?

HCA Healthcare Inc. generated $5.97B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $11.17B less capital expenditures.

What is HCA earnings per share?

Diluted earnings per share were $30.13 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did HCA last report financial results?

The latest statements here come from HCA Healthcare Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Where does this HCA financial data come from?

Quantisnow builds these statements from the structured XBRL data HCA Healthcare Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · HCA

HCA Healthcare Inc. (HCA) financials

For the twelve months ended Sep 30, 2026, HCA Healthcare Inc. reported $78.70B of revenue and $6.78B of net income.

Revenue, TTM: $78.70B
Revenue growth, YoY: +5.8%
Net income, TTM: $6.78B
Net income growth, YoY: +6.8%
Net margin: 8.6%
Free cash flow, TTM: $5.97B
EPS, diluted, TTM: $30.13
EPS growth, YoY: +16.3%
Cash: $908.00M
Total debt: $50.49B
P/E: 15.26
P/S: 1.31
Market cap: $103.40B

Annual revenue$75.60B

FY2016FY2025

Annual net income$6.78B

FY2016FY2025

Annual free cash flow$7.69B

FY2016FY2025

HCA revenue and earnings growth

HCA revenueQ3 2026$19.85B

Quarter YoY: +3.6%
QoQ: -1.9%
FY YoY: +7.1%
5Y CAGR: +8.0%

HCA revenue was $19.85B in fiscal Q3 2026 (ended Sep 30, 2026), up 3.6% from a year earlier and down 1.9% from the prior quarter. For the full fiscal 2025 it was $75.60B, up 7.1% from fiscal 2024. Compound annual growth was +8.0% over 5 years. It rose in each of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

HCA net incomeQ3 2026$1.58B

Quarter YoY: -3.9%
QoQ: -7.1%
FY YoY: +17.8%
5Y CAGR: +12.6%
10Y CAGR: +12.3%

HCA net income was $1.58B in fiscal Q3 2026 (ended Sep 30, 2026), down 3.9% from a year earlier and down 7.1% from the prior quarter. For the full fiscal 2025 it was $6.78B, up 17.8% from fiscal 2024. Compound annual growth was +12.6% over 5 years and +12.3% over 10 years. It rose in 6 of the last 10 fiscal years.

HCA EPSQ3 2026$7.27

Quarter YoY: +4.5%
QoQ: -4.6%
FY YoY: +28.8%
5Y CAGR: +21.0%
10Y CAGR: +19.0%

HCA diluted EPS was $7.27 in fiscal Q3 2026 (ended Sep 30, 2026), up 4.5% from a year earlier and down 4.6% from the prior quarter. For the full fiscal 2025 it was $28.33, up 28.8% from fiscal 2024. Compound annual growth was +21.0% over 5 years and +19.0% over 10 years.

HCA free cash flowQ3 2026$3.10B

Quarter YoY: -0.8%
QoQ: +181.2%
FY YoY: +36.4%
5Y CAGR: +3.8%
10Y CAGR: +12.5%

HCA free cash flow was $3.10B in fiscal Q3 2026 (ended Sep 30, 2026), down 0.8% from a year earlier and up 181.2% from the prior quarter. For the full fiscal 2025 it was $7.69B, up 36.4% from fiscal 2024. Compound annual growth was +3.8% over 5 years and +12.5% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$75.60B	$70.60B	$64.97B	$60.23B	$58.75B	$51.53B	$51.34B	$46.68B	$43.61B	$41.49B
Selling, general and admin	$548.00M	$421.00M	$353.00M	$307.00M	$337.00M	$416.00M	$370.00M	$344.00M	$340.00M	$343.00M
Interest expense	$2.25B	$2.06B	$1.94B	$1.74B	$1.57B	$1.58B	$1.82B	$1.75B	$1.69B	$1.71B
Pre-tax income	$9.83B	$8.52B	$7.71B	$8.58B	$9.83B	$5.43B	$5.24B	$5.33B	$4.38B	$4.81B
Income tax	$2.05B	$1.87B	$1.61B	$1.75B	$2.11B	$1.04B	$1.10B	$946.00M	$1.64B	$1.38B
Net income	$6.78B	$5.76B	$5.24B	$5.64B	$6.96B	$3.75B	$3.50B	$3.79B	$2.22B	$2.89B
EPS, basic	$28.70	$22.27	$19.25	$19.43	$21.52	$11.10	$10.27	$10.90	$6.12	$7.53
EPS, diluted	$28.33	$22.00	$18.97	$19.15	$21.16	$10.93	$10.07	$10.66	$5.95	$7.30
Diluted shares	239.5M	261.8M	276.4M	294.7M	328.8M	343.6M	348.2M	355.3M	372.2M	395.9M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$1.04B	$1.93B	$935.00M	$908.00M	$1.45B	$1.79B	$621.00M	$502.00M	$732.00M	$646.00M
Receivables	$10.87B	$10.75B	$9.96B	$8.89B	$8.10B	$7.05B	$7.38B	$6.79B	$6.50B	$5.83B
Inventory	$1.65B	$1.74B	$2.02B	$2.07B	$1.99B	$2.02B	$1.85B	$1.73B	$1.57B	$1.50B
Current assets	$15.78B	$16.41B	$14.93B	$13.64B	$13.54B	$12.33B	$11.20B	$10.21B	$9.98B	$9.09B
Total assets	$60.72B	$59.51B	$56.21B	$52.44B	$50.74B	$47.49B	$45.06B	$39.21B	$36.59B	$33.76B
Current liabilities	$16.35B	$15.18B	$12.65B	$9.90B	$9.58B	$8.70B	$7.76B	$7.57B	$6.16B	$5.83B
Short-term debt	$4.89B	$4.70B	$2.42B	$370.00M	$237.00M	$209.00M	$145.00M	$788.00M	$200.00M	$216.00M
Long-term debt	$41.60B	$38.33B	$37.17B	$37.71B	$34.34B	$30.80B	$33.58B	$32.03B	$32.86B	$31.16B
Total debt	$46.49B	$43.03B	$39.59B	$38.08B	$34.58B	$31.00B	$33.72B	$32.82B	$33.06B	$31.38B
Total liabilities	$63.49B	$58.96B	$55.15B	$52.51B	$49.25B	$44.60B	$45.62B	$42.13B	$41.59B	$39.39B
Shareholders' equity	-$6.03B	$555.00M	$1.06B	-$73.00M	$1.49B	$2.89B	-$565.00M	-$2.92B	-$5.00B	-$5.63B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$12.64B	$10.51B	$9.43B	$8.52B	$8.96B	$9.23B	$7.60B	$6.76B	$5.43B	$5.65B
Capital expenditures	$4.94B	$4.88B	$4.74B	$4.39B	$3.58B	$2.83B	$4.16B	$3.57B	$3.02B	$2.76B
Free cash flow	$7.69B	$5.64B	$4.69B	$4.13B	$5.38B	$6.40B	$3.44B	$3.19B	$2.41B	$2.89B
Investing cash flow	-$4.99B	-$4.93B	-$5.32B	-$3.39B	-$2.64B	-$3.39B	-$5.72B	-$3.90B	-$4.28B	-$3.24B
Financing cash flow	-$8.55B	-$4.58B	-$4.09B	-$5.66B	-$6.66B	-$4.68B	-$1.77B	-$3.08B	-$1.06B	-$2.51B
Dividends paid	$679.00M	$690.00M	$661.00M	$653.00M	$624.00M	$153.00M	$550.00M	$487.00M	$0	-
Share repurchases	$10.07B	$6.04B	$3.81B	$7.00B	$8.21B	$441.00M	$1.03B	$1.53B	$2.05B	$2.75B
Stock-based compensation	$401.00M	$360.00M	$262.00M	$341.00M	$440.00M	$362.00M	$347.00M	$268.00M	$270.00M	$251.00M
Depreciation and amortization	$3.52B	$3.31B	$3.08B	$2.97B	$2.85B	$2.72B	$2.60B	$2.28B	$2.13B	$1.97B

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	7.1%	8.7%	7.9%	2.5%	14.0%	0.4%	10.0%	7.0%	5.1%	-
Net income growth, YoY	17.8%	9.9%	-7.1%	-18.9%	85.3%	7.1%	-7.4%	70.9%	-23.3%	35.7%
EPS growth, YoY	28.8%	16.0%	-0.9%	-9.5%	93.6%	8.5%	-5.5%	79.2%	-18.5%	46.3%
Net margin	9.0%	8.2%	8.1%	9.4%	11.8%	7.3%	6.8%	8.1%	5.1%	7.0%
Free cash flow margin	10.2%	8.0%	7.2%	6.9%	9.2%	12.4%	6.7%	6.8%	5.5%	7.0%
Return on equity	-	1037.8%	494.5%	-	467.2%	129.8%	-	-	-	-
Return on assets	11.2%	9.7%	9.3%	10.8%	13.7%	7.9%	7.8%	9.7%	6.1%	8.6%
Current ratio	0.97	1.08	1.18	1.38	1.41	1.42	1.44	1.35	1.62	1.56
Debt to equity	-	77.53	37.35	-	23.22	10.72	-	-	-	-

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$19.85B	$20.23B	$19.11B	$19.51B	$19.16B	$18.61B	$18.32B	$18.29B	$17.49B	$17.49B	$17.34B	$17.30B
Selling, general and admin	$146.00M	$148.00M	$133.00M	$153.00M	$139.00M	$130.00M	$126.00M	$120.00M	$111.00M	$100.00M	$90.00M	$100.00M
Interest expense	$607.00M	$599.00M	$584.00M	$572.00M	$561.00M	$568.00M	$547.00M	$528.00M	$515.00M	$506.00M	$512.00M	$491.00M
Pre-tax income	$2.37B	$2.49B	$2.29B	$2.67B	$2.42B	$2.42B	$2.33B	$2.13B	$1.91B	$2.24B	$2.25B	$2.35B
Income tax	$521.00M	$564.00M	$430.00M	$509.00M	$515.00M	$524.00M	$502.00M	$447.00M	$424.00M	$550.00M	$445.00M	$484.00M
Net income	$1.58B	$1.70B	$1.62B	$1.88B	$1.64B	$1.65B	$1.61B	$1.44B	$1.27B	$1.46B	$1.59B	$1.61B
EPS, basic	$7.36	$7.70	$7.25	$8.22	$7.05	$6.91	$6.52	$5.72	$4.94	$5.60	$6.01	$6.00
EPS, diluted	$7.27	$7.62	$7.15	$8.09	$6.96	$6.83	$6.45	$5.66	$4.88	$5.53	$5.93	$5.92
Diluted shares	217.2M	222.8M	226.7M	-	236.2M	241.9M	249.4M	-	259.9M	264.1M	268.0M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$908.00M	$1.01B	$940.00M	$1.04B	$997.00M	$939.00M	$1.06B	$1.93B	$2.89B	$831.00M	$1.28B	$935.00M
Receivables	$11.51B	$12.28B	$11.32B	$10.87B	$10.43B	$10.46B	$11.09B	$10.75B	$9.91B	$10.24B	$10.04B	$9.96B
Inventory	$1.67B	$1.66B	$1.68B	$1.65B	$1.73B	$1.79B	$1.79B	$1.74B	$1.78B	$1.80B	$1.90B	$2.02B
Current assets	$16.22B	$17.19B	$16.05B	$15.78B	$15.29B	$15.56B	$16.26B	$16.41B	$16.66B	$15.17B	$15.28B	$14.93B
Total assets	$63.45B	$63.25B	$61.45B	$60.72B	$59.75B	$59.54B	$59.80B	$59.51B	$59.46B	$57.38B	$56.96B	$56.21B
Current liabilities	$19.78B	$17.31B	$19.26B	$16.35B	$17.90B	$15.94B	$13.63B	$15.18B	$14.90B	$14.30B	$13.14B	$12.65B
Short-term debt	$8.09B	$6.26B	$8.53B	$4.89B	$6.11B	$5.10B	$3.52B	$4.70B	$4.68B	$4.57B	$3.03B	$2.42B
Long-term debt	$42.40B	$43.45B	$39.49B	$41.60B	$38.40B	$39.38B	$41.06B	$38.33B	$38.28B	$36.31B	$37.16B	$37.17B
Total debt	$50.49B	$49.72B	$48.02B	$46.49B	$44.51B	$44.48B	$44.58B	$43.03B	$42.97B	$40.88B	$40.19B	$39.59B
Total liabilities	$68.05B	$66.46B	$64.43B	$63.49B	$61.91B	$60.77B	$60.24B	$58.96B	$58.67B	$56.04B	$55.69B	$55.15B
Shareholders' equity	-$8.08B	-$3.21B	-$2.98B	-$6.03B	-$2.16B	-$1.24B	-$438.00M	$555.00M	$786.00M	$1.34B	$1.27B	$1.06B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$4.46B	$2.33B	$2.01B	$2.36B	$4.42B	$4.21B	$1.65B	$2.56B	$3.52B	$1.97B	$2.47B	$2.67B
Capital expenditures	$1.36B	$1.23B	$1.12B	$1.49B	$1.29B	$1.18B	$991.00M	$1.28B	$1.19B	$1.28B	$1.12B	$1.16B
Free cash flow	$3.10B	$1.10B	$895.00M	$870.00M	$3.13B	$3.03B	$660.00M	$1.27B	$2.32B	$690.00M	$1.35B	$1.51B
Investing cash flow	-$1.92B	-$1.56B	-$1.28B	-$1.32B	-$1.39B	-$1.25B	-$1.03B	-$1.35B	-$1.35B	-$1.33B	-$903.00M	-$1.60B
Financing cash flow	-$2.65B	-$704.00M	-$830.00M	-$999.00M	-$2.97B	-$3.09B	-$1.50B	-$2.16B	-$110.00M	-$1.09B	-$1.22B	-$1.04B
Dividends paid	$165.00M	$171.00M	$183.00M	$162.00M	$166.00M	$171.00M	$180.00M	$165.00M	$169.00M	$171.00M	$185.00M	$160.00M
Share repurchases	$2.97B	$2.06B	$1.57B	$2.56B	$2.50B	$2.50B	$2.51B	$1.70B	$1.79B	$1.37B	$1.18B	$910.00M
Stock-based compensation	$133.00M	$85.00M	$86.00M	$100.00M	$104.00M	$99.00M	$98.00M	$85.00M	$76.00M	$112.00M	$87.00M	$57.00M
Depreciation and amortization	$954.00M	$944.00M	$930.00M	$911.00M	$889.00M	$863.00M	$860.00M	$856.00M	$842.00M	$819.00M	$795.00M	$789.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	3.6%	8.7%	4.3%	6.7%	9.6%	6.4%	5.7%	5.7%	7.9%	10.3%	11.2%	11.7%
Net income growth, YoY	-3.9%	2.8%	0.6%	30.6%	29.4%	13.1%	1.2%	-10.5%	17.7%	22.5%	16.7%	-22.8%
EPS growth, YoY	4.5%	11.6%	10.9%	42.9%	42.6%	23.5%	8.8%	-4.4%	24.8%	28.9%	22.3%	-17.8%
Net margin	8.0%	8.4%	8.5%	9.6%	8.6%	8.9%	8.8%	7.9%	7.3%	8.4%	9.2%	9.3%
Free cash flow margin	15.6%	5.5%	4.7%	4.5%	16.3%	16.3%	3.6%	7.0%	13.3%	3.9%	7.8%	8.8%
Current ratio	0.82	0.99	0.83	0.97	0.85	0.98	1.19	1.08	1.12	1.06	1.16	1.18
Debt to equity	-	-	-	-	-	-	-	77.53	54.66	30.53	31.65	37.35

Source: XBRL data HCA Healthcare Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

HCA peers

Company	Revenue	Growth	Net income	Net margin	Market cap
HCA	$78.70B	+5.8%	$6.78B	8.6%	$103.40B
THCTenet Healthcare Corporation	$22.15B	+6.2%	$2.90B	13.1%	$22.55B
EHCEncompass Health Corporation	$6.34B	+9.4%	$644.40M	10.2%	$13.50B
UHSUniversal Health Services Inc.	$18.35B	+8.0%	$1.46B	8.0%	$11.52B
ENSGThe Ensign Group Inc.	$5.67B	+17.5%	$399.12M	7.0%	$10.56B
PACSPACS Group Inc.	$5.71B	+11.0%	$277.58M	4.9%	$7.87B
NHCNational HealthCare Corporation	$1.58B	+5.6%	$115.13M	7.3%	$3.27B
SGRYSurgery Partners Inc.	$3.37B	+4.0%	-$88.60M	-2.6%	$3.04B
MDPediatrix Medical Group Inc.	$1.96B	+1.9%	$150.09M	7.7%	$2.44B

HCA FAQ

8 questions

What is HCA revenue?
HCA Healthcare Inc. (HCA) reported $78.70B of revenue for the twelve months ended Sep 30, 2026. That is up 5.8% from the year before. Revenue for fiscal 2025 was $75.60B.
Is HCA profitable?
Yes. HCA Healthcare Inc. earned $6.78B in net income for the twelve months ended Sep 30, 2026, a net margin of 8.6%.
How much cash and debt does HCA have?
HCA Healthcare Inc. reported $908.00M in cash and cash equivalents and $50.49B of debt on its most recent balance sheet in SEC filings.
How fast is HCA revenue growing?
HCA Healthcare Inc.'s revenue changed +7.1% in fiscal 2025, to $75.60B. Its compound annual growth rate was +8.0% over 5 years.
What is HCA free cash flow?
HCA Healthcare Inc. generated $5.97B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $11.17B less capital expenditures.
What is HCA earnings per share?
Diluted earnings per share were $30.13 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did HCA last report financial results?
The latest statements here come from HCA Healthcare Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this HCA financial data come from?
Quantisnow builds these statements from the structured XBRL data HCA Healthcare Inc. files with the SEC. It is provided for information only and is not investment advice.